Cargando…
Do Decision-Analytic Models Identify Cost-Effective Treatments? A Retrospective Look at Helicobacter Pylori Eradication
BACKGROUND: Pharmacoeconomic models of Helicobacter (H) pylori eradication have been frequently cited but never validated. OBJECTIVES: Examine retrospectively whether H pylori pharmacoeconomic models direct decision makers to cost-effective therapeutic choices. METHODS: We first replicated and then...
Autores principales: | Fairman, Kathleen A., Motheral, Brenda R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437262/ https://www.ncbi.nlm.nih.gov/pubmed/14613441 http://dx.doi.org/10.18553/jmcp.2003.9.5.430 |
Ejemplares similares
-
Cost-Effectiveness Analysis and the Formulary Decision-Making Process
por: Wang, Zhixiao, et al.
Publicado: (2004) -
Cost Implications of Formulary Decisions on Oral Anticoagulants in Nonvalvular Atrial Fibrillation
por: Biskupiak, Joseph, et al.
Publicado: (2013) -
Critical Review of Prasugrel for Formulary Decision Makers
por: Schafer, Jeremy
Publicado: (2009) -
Determinants of the Cost-Effectiveness of Statins
por: Morrison, Alan, et al.
Publicado: (2003) -
Cost-Effectiveness of Tamsulosin, Doxazosin, and Terazosin in the Treatment of Benign Prostatic Hyperplasia
por: Ohsfeldt, Robert L., et al.
Publicado: (2004)